|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.92 USD | -3.95% |
|
-33.13% | -47.66% |
| 12-05 | Top Premarket Decliners | MT |
| 11-11 | Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies | CI |
Evolution of the Average Target: Quoin Pharmaceuticals, Ltd.
Evolution of the Target Price: Quoin Pharmaceuticals, Ltd.
Changes in Analyst Recommendations: Quoin Pharmaceuticals, Ltd.
74c1fd5b1d5fb0e410c5bbee5005.O7el3vgom2TgTS-_jFS-11jdVp5Qevj70QAsZqzaqBw.S_OSuL151giPKVyLtCzT4BefNfYBSM6KuThcDpm45ylj4cKsrWSjJ9IlGw~a72c07b3697054a5549e6b309fd904f4
More recommendations
Analysts' Consensus
Sell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.92USD
Average target price
40.67USD
Spread / Average Target
+241.16%
High Price Target
70.00USD
Spread / Highest target
+487.25%
Low Price Target
25.00USD
Spread / Lowest Target
+109.73%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Maxim | |
| Ladenburg Thalmann | |
| JMP Securities | |
| Alliance Global Partners |
Sell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.92USD
Average target price
40.67USD
Spread / Average Target
+241.16%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- QNRX Stock
- Consensus Quoin Pharmaceuticals, Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















